var data={"title":"Factor VIIa (activated), recombinant human: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Factor VIIa (activated), recombinant human: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6171?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=factor-viia-activated-recombinant-human-drug-information\" class=\"drug drug_general\">see &quot;Factor VIIa (activated), recombinant human: Drug information&quot;</a> and <a href=\"topic.htm?path=factor-viia-activated-recombinant-human-patient-drug-information\" class=\"drug drug_patient\">see &quot;Factor VIIa (activated), recombinant human: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10053630\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Thrombosis: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious arterial and venous thrombotic events following administration of Factor VIIa (recombinant) have been reported. Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive Factor VIIa (recombinant). Monitor patients for signs and symptoms of activation of the coagulation system and for thrombosis. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169443\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>NovoSeven RT</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169444\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Niastase;</li>\n      <li>Niastase RT</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058582\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihemophilic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29245387\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glanzmann's thrombasthenia:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Bleeding episodes, severe (refractory to platelet transfusions):</i> 90 mcg/kg/dose every 2 to 6 hours until hemostasis is achieved</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Perioperative management:</i> 90 mcg/kg immediately before surgery; repeat at 2-hour intervals for the duration of surgery. Continue 90 mcg/kg/dose every 2 to 6 hours to prevent postoperative bleeding. <b>Note:</b> Higher average infused doses (median: 100 mcg/kg) were noted for surgical patients who had clinical refractoriness with or without platelet-specific antibodies compared to those with neither.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058575\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=factor-viia-activated-recombinant-human-drug-information\" class=\"drug drug_general\">see &quot;Factor VIIa (activated), recombinant human: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hemophilia A or B (congenital) with inhibitors:</b> Infants, Children, and Adolescents: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bleeding episodes:</i> 90 mcg/kg every 2 hours until hemostasis is achieved or until the treatment is judged ineffective. Doses between 35 to 90 mcg/kg have been used successfully in clinical trials. The dose, interval, and duration of therapy may be adjusted based on severity of bleeding and the degree of hemostasis achieved. For patients treated for joint or muscle bleeds, a decision on the outcome of treatment was reached within 8 doses in the majority of patients, although more doses were required for severe bleeds; adverse effects were reported most commonly in patients treated with 12 or more doses. For patients experiencing severe bleeds to maintain the hemostatic plug, dosing should be continued at 3- to 6-hour intervals; the duration of posthemostatic dosing should be minimized. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Perioperative management:</i> 90 mcg/kg immediately before surgery (additional bolus doses may be administered for major surgery if required); repeat at 2-hour intervals for the duration of surgery. For minor surgery, continue 90 mcg/kg every 2 hours for 48 hours, then every 2 to 6 hours until healed. For major surgery, continue 90 mcg/kg every 2 hours for 5 days, then every 4 hours until healed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Congenital factor VII deficiency:</b> Infants, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bleeding episodes:</i> 15 to 30 mcg/kg every 4 to 6 hours until hemostasis is achieved. Doses as low as 10 mcg/kg have been effective.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Perioperative management:</i> 15 to 30 mcg/kg immediately before surgery; repeat every 4 to 6 hours for the duration of surgery and until hemostasis achieved. Doses as low as 10 mcg/kg have been effective. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Glanzmann's thrombasthenia:</b> Infants, Children, and Adolescents:  IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bleeding episodes, severe (refractory to platelet transfusions):</i> 90 mcg/kg/dose every 2 to 6 hours until hemostasis is achieved</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Perioperative management:</i> 90 mcg/kg immediately before surgery; repeat at 2-hour intervals for the duration of surgery. Continue 90 mcg/kg/dose every 2 to 6 hours to prevent postoperative bleeding. <b>Note:</b> Higher average infused doses (median: 100 mcg/kg) were noted for surgical patients who had clinical refractoriness with or without platelet-specific antibodies compared to those with neither.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hemophilia A or B, congenital; with inhibitors:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bleeding episodes:</i> 90 mcg/kg every 2 hours until hemostasis is achieved or until the treatment is judged ineffective. Doses between 35 and 90 mcg/kg have been used successfully in clinical trials. The dose, interval, and duration of therapy may be adjusted based upon the severity of bleeding and the degree of hemostasis achieved. For patients experiencing severe bleeds, dosing should be continued at 3- to 6-hour intervals after hemostasis has been achieved and the duration of dosing should be minimized. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Perioperative management:</i> 90 mcg/kg immediately before surgery (additional bolus doses may be administered for major surgery if required); repeat at 2-hour intervals for the duration of surgery. For minor surgery, continue 90 mcg/kg every 2 hours for 48 hours, then every 2 to 6 hours until healed. For major surgery, continue 90 mcg/kg every 2 hours for 5 days, then every 4 hours until healed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Congenital factor VII deficiency:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bleeding episodes:</i> 15 to 30 mcg/kg every 4 to 6 hours until hemostasis is achieved. Doses as low as 10 mcg/kg have been effective.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Perioperative management:</i> 15 to 30 mcg/kg immediately before surgery; repeat every 4 to 6 hours for the duration of surgery and until hemostasis achieved. Doses as low as 10 mcg/kg have been effective. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acquired hemophilia:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bleeding episodes:</i> 70 to 90 mcg/kg every 2 to 3 hours until hemostasis is achieved</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Perioperative management:</i> 70 to 90 mcg/kg immediately before surgery; repeat every 2 to 3 hours for the duration of surgery and until hemostasis achieved</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Glanzmann's thrombasthenia:</b>  IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bleeding episodes (refractory to platelet transfusions):</i> 90 mcg/kg every 2 to 6 hours until hemostasis is achieved</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Perioperative management:</i> 90 mcg/kg immediately before surgery; repeat at 2-hour intervals for the duration of surgery. Continue 90 mcg/kg every 2 to 6 hours to prevent postoperative bleeding. <b>Note:</b> Higher average infused doses (median: 100 mcg/kg) were noted for surgical patients who had clinical refractoriness with or without platelet-specific antibodies compared to those with neither.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169430\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NovoSeven RT: 1 mg (1 ea); 2 mg (1 ea); 5 mg (1 ea); 8 mg (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169417\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058585\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: IV: NovoSeven RT: Prior to reconstitution, bring to a temperature not above 37&deg;C (98.6&deg;F). Add recommended diluent along wall of vial; do not inject directly onto powder. Gently swirl until dissolved. Do not mix with other infusion solutions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NovoSeven RT: Reconstitute each vial to a final concentration of 1 mg/mL using the provided histidine diluent as follows: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 mg vial: 1.1 mL histidine diluent </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">2 mg vial: 2.1 mL histidine diluent </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">5 mg vial: 5.2 mL histidine diluent </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">8 mg vial: 8.1 mL histidine diluent </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Administer as a slow bolus over 2 to 5 minutes. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169440\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">NovoSeven RT: Prior to reconstitution, store between 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F); do not freeze. Protect from light. Reconstituted solutions may be stored at room temperature or under refrigeration, but must be infused within 3 hours of reconstitution. Do not freeze reconstituted solutions. Do not store reconstituted solutions in syringes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058584\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of bleeding episodes and perioperative management in surgical interventions in patients with either congenital hemophilia A or B when inhibitors to factor VIII or factor IX are present, or congenital factor VII deficiency (FDA approved in pediatric patients [age not specified] and adults); treatment of bleeding episodes and perioperative management in surgical interventions in patients with Glanzmann&rsquo;s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets (FDA approved in all patients); treatment of bleeding episodes and perioperative management in patients with acquired hemophilia (FDA approved in adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169463\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Bradycardia, edema, hypertension, hypotension, thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Cerebrovascular disease, headache, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Decreased serum fibrinogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Decreased prothrombin time, disseminated intravascular coagulation, increased fibrinolysis, purpura</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Abnormal hepatic function tests</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Osteoarthrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Renal function abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Pneumonia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Decreased therapeutic response, fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Anaphylactic shock, anaphylaxis, angina pectoris, angioedema, antibody development, arterial embolism (retinal), arterial thrombosis, arterial thrombosis (limb, retinal), bowel infarction, cerebral infarction, cerebral ischemia, cerebrovascular accident, deep vein thrombosis, hepatic artery thrombosis, hypersensitivity, immunogenicity, increased fibrin degradation products (including D-dimer elevation), intracardiac thrombus, local phlebitis, myocardial infarction, myocardial ischemia, nausea, occlusion of cerebral arteries, peripheral ischemia, portal vein thrombosis, pulmonary embolism, renal artery thrombosis, thrombophlebitis, venous thrombosis at injection site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169435\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to eptacog alfa, any component of the formulation, or mouse, hamster or bovine protein</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169420\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Antibody formation: In patients with factor VII deficiency, if factor VIIa activity does not reach the expected level, prothrombin time is not corrected, or bleeding is uncontrolled (with recommended doses), suspect antibody formation and perform antibody analysis. Prothrombin time and factor VII coagulant activity should be measured before and after administration in patients with factor VII deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, have been reported with use. Use with caution in patients with known hypersensitivity to mouse, hamster, or bovine proteins, or factor VIIa, or any components of the product. If hypersensitivity reaction occurs, discontinue use and administer appropriate treatment; carefully consider the benefits versus the risk of continued treatment with factor VIIa.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thromboembolic events: <b>[US Boxed Warning]: Serious arterial and venous thrombotic events following administration of Factor VIIa (recombinant) have been reported. Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive factor VIIa (recombinant). Monitor patients for signs and symptoms of activation of the coagulation system and for thrombosis.</b> All patients receiving factor VIIa should be monitored for signs and symptoms of activation of the coagulation system or thrombosis; thrombotic events may be increased due to circulating tissue factor or predisposing coagulopathy in patients with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, septicemia, crush injury, concomitant treatment with activated or nonactivated prothrombin complex concentrates, or uncontrolled postpartum hemorrhage. Use with caution in patients with an increased risk of thromboembolic complications (eg, coronary heart disease, liver disease, DIC, postoperative immobilization, elderly patients, and neonates). Decreased dosage or discontinuation is warranted with confirmed intravascular coagulation or presence of clinical thrombosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens).  Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Reduced efficacy: A number of factors influence the efficacy of factor VIIa, including hypothermia, thrombocytopenia, acidosis, and the amount of blood products transfused prior to administration (Dunkley, 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299309\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220313\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12916&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Emicizumab-kxwh: May enhance the thrombogenic effect of Factor VIIa (Recombinant).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Factor XIII A-Subunit (Recombinant): May enhance the thrombogenic effect of Factor VIIa (Recombinant).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2181984\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Factor VII concentrations may vary significantly in pregnant women with coagulation disorders. Pregnant women with hemophilia should have clotting factors monitored, particularly at 28 and 34 weeks gestation and prior to invasive procedures. Recombinant factor VIIa is recommended for the management of bleeding disorders in pregnant women with factor VII deficiency. Prophylaxis at delivery may be needed if factor VII concentrations are &lt;10 to 20 units /dL or in women with a significant bleeding history and treatment should continue for 3 to 5 days postpartum depending on route of delivery. The neonate may also be at an increased risk of bleeding following delivery and should be tested for the coagulation disorder (Kadir 2009; Lee 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058581\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for evidence of hemostasis and thrombosis (including laboratory confirmation of intravascular coagulation, if appropriate). Although the prothrombin time (PT)/INR, aPTT, and factor VII clotting activity have shown no direct correlation with achieving clinical hemostasis, these parameters may be useful as adjunct tests to evaluate efficacy and guide dose or interval adjustments. In factor VII-deficient patients, monitor PT and factor VII clotting activity before and after administration; if the factor VIIa activity fails to reach the expected level, if PT is not corrected, or if bleeding is not controlled after treatment with recommended doses, monitor for factor VII antibodies.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169419\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Recombinant factor VIIa, a vitamin K-dependent glycoprotein, promotes hemostasis by activating the extrinsic pathway of the coagulation cascade. It replaces deficient activated coagulation factor VII, which complexes with tissue factor and may activate coagulation factor X to Xa and factor IX to IXa. When complexed with other factors, coagulation factor Xa converts prothrombin to thrombin, a key step in the formation of a fibrin-platelet hemostatic plug.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169434\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemophilia A or B:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Distribution: V<sub>ss</sub>: Children 2 to 12 years: 164 mL/kg; Adults: 107 to 128 mL/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Half-life, terminal: Children 2 to 12 years: 2.6 hours; Adults: 2.9 to 3.1 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Excretion: Clearance: Children 2 to 12 years: 58 mL/hour/kg; Adults: 31 to 39 mL/hour/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Factor VII deficiency:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Distribution: V<sub>ss</sub>: 280 to 290 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Half-life, terminal: 2.8 to 3.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Excretion: Clearance: 71 to 79 mL/kg/hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058590\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Each mg factor VIIa contains 0.4 mEq sodium and 0.01 mEq calcium</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323142\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (NovoSeven RT Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (0 Price provided is per microgram): $2.59</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (0 Price provided is per microgram): $2.59</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (0 Price provided is per microgram): $2.59</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (0 Price provided is per microgram): $2.59</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169437\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Novonordisk (MX);</li>\n      <li>NovoSeven (AE, AR, AT, BE, BG, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IL, IN, IS, IT, JO, KR, KW, LB, LT, LU, LV, MT, MY, NL, NO, NZ, PE, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UA, UY);</li>\n      <li>Novoseven (MX);</li>\n      <li>Novoseven RT (AU, CR, CU, DO, GT, HN, NI, PA, SV, VN);</li>\n      <li>NovoSeven RT (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dunkley S, Phillips L, McCall P, et al. Recombinant activated factor VII in cardiac surgery: Experience from the Australian and New Zealand Haemostasis Registry. <i>Ann Thorac Surg</i>. 2008;85:836-844.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Novoseven RT (coagulation factor viia [recombinant]) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12916 Version 91.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F10053630\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F169443\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F169444\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058582\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F29245387\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1058575\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F169430\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F169417\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058585\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F169440\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058584\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F169463\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F169435\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F169420\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299309\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220313\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2181984\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1058581\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F169419\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F169434\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1058590\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323142\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F169437\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12916|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=factor-viia-activated-recombinant-human-drug-information\" class=\"drug drug_general\">Factor VIIa (activated), recombinant human: Drug information</a></li><li><a href=\"topic.htm?path=factor-viia-activated-recombinant-human-patient-drug-information\" class=\"drug drug_patient\">Factor VIIa (activated), recombinant human: Patient drug information</a></li></ul></div></div>","javascript":null}